What is the average yearly salary for a Software Engineer at Veracyte in the United States?
The average annual salary for a Software Engineer employed by Veracyte, Inc. in the United States is approximately USD 147,592, which places compensation roughly 30 percent above the national average baseline for standard software engineering roles. Total remuneration packages frequently incorporate competitive base salaries, annual performance cash bonuses, stock options, and comprehensive health benefits designed to attract specialized engineering talent within the biotechnology and molecular diagnostics sector.
Related FAQs
Vector Marketing—the direct sales company famous for marketing Cutco kitchen cutlery through independent sales representatives—compensates its representatives primarily through a commission-based structure tied directly to product sales performance.
Veracyte, Inc. (NASDAQ: VCYT) trades at approximately $46.32 per share.
Veracyte stock maintains a favorable future outlook supported by strong analyst consensus ratings and growing confidence in its molecular diagnostics portfolio.
Veracyte (NASDAQ: VCYT) is frequently evaluated by healthcare and biotechnology analysts as an intriguing long-term growth investment for portfolios seeking exposure to genomic diagnostics and precision oncology.
Evaluating whether the present moment is ideal for purchasing the Vanguard Total Stock Market Index Fund (VTI) depends heavily on an investor's individual timeline, risk tolerance, and portfolio strategy.
Viasat anticipates an evolving future outlook shaped by its strategic transition toward advanced satellite communication networks, inflight connectivity services, and defense communications contracts.
Veralto Corporation is a global leader in essential technology solutions focused on water quality and product quality, serving customers across multiple continents.
A Veracyte test refers to an advanced genomic diagnostic test developed by Veracyte, a molecular diagnostics company specializing in precision oncology and genomic sequencing.
Veracyte, Inc. possesses strong long-term growth prospects driven by its innovative genomic diagnostics platform, which focuses on advanced molecular testing for oncology and specialized chronic diseases.
Veracyte is a pioneering global diagnostics and biotechnology company dedicated to improving patient care by transforming the diagnosis and treatment of challenging diseases through advanced genomic technology.
Veracyte, Inc. is officially headquartered at 6000 Shoreline Court, Suite 300, South San Francisco, California 94080, United States.
Veracyte generates robust annual revenues driven by strong commercial adoption of its genomic testing portfolios, diagnostic assays, and biopharmaceutical collaborations.
Veracyte Inc. operates as a fully public corporate enterprise, with its common shares listed and traded on the Nasdaq stock exchange under the ticker symbol VCYT.
Veracyte anticipates an exceptionally strong future growth outlook driven by expanding clinical adoption of its advanced genomic diagnostics, including Afirma, Percepta, and the novel TrueMRD platform.
Veracyte, Inc., trading under the ticker VCTC, operates as a specialized genomic diagnostics company providing advanced clinical testing and cancer diagnostic solutions designed to improve patient care outcomes.
Equity research analysts covering Veracyte, Inc. maintain a strong consensus "Buy" rating, reflecting robust institutional confidence in its genomic diagnostics business model.
Veracyte, Inc. was officially founded in 2008 by a team of life science entrepreneurs and clinical diagnostic pioneers dedicated to transforming cancer diagnosis through advanced genomic technology.
Veracyte stock prices are primarily influenced by clinical diagnostics adoption rates, genomic test requisition volumes, and reimbursement coverage developments from major public and private health insurers.
Employees and scientific professionals working at Veracyte report a collaborative, mission-driven corporate culture focused on advancing genomic testing to improve cancer diagnosis and patient care.
Equity research analysts tracking Veracyte (NASDAQ: VCYT) typically assign favorable buy or moderate buy consensus ratings, highlighting its strong commercial execution in genomic diagnostics and precision oncology testing.
Equity research analysts and long-term financial valuation models projecting Viasat shares through the end of the decade anticipate potential valuation recovery and growth.
Veracyte is a global diagnostics and biotechnology enterprise that specializes in improving cancer diagnosis and treatment decision-making through advanced genomic technology.
Veracyte is a molecular diagnostics enterprise that offers advanced genomic tests designed to improve cancer diagnosis and guide personalized treatment decisions.
Equity research analysts evaluate Novacyt SA and related molecular diagnostics enterprises with evolving long-term growth prospects, centered on clinical diagnostic product development, polymerase chain reaction assay technologies, and health securit...